» Articles » PMID: 37762308

Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility to Infections

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Sep 28
PMID 37762308
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder caused by the deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) and often leads to pulmonary infections caused by various pathogens, including , , and nontuberculous mycobacteria, particularly . Unfortunately, infections are increasing in prevalence and are associated with the rapid deterioration of CF patients. The treatment options for infections are limited, requiring the urgent need to comprehend infectious pathogenesis and develop new therapeutic interventions targeting affected CF patients. Here, we show that the deficiency of CFTR reduces sphingosine levels in bronchial and alveolar epithelial cells and macrophages from CF mice and humans. Decreased sphingosine contributes to the susceptibility of CF tissues to infection, resulting in a higher incidence of infections in CF mice. Notably, treatment of with sphingosine demonstrated potent bactericidal activity against the pathogen. Most importantly, restoration of sphingosine levels in CF cells, whether human or mouse, and in the lungs of CF mice, provided protection against infections. Our findings demonstrate that pulmonary sphingosine levels are important in controlling infection. These results offer a promising therapeutic avenue for CF patients with pulmonary infections.

Citing Articles

The genes are important for growth in the presence of sphingosine by promoting sphingosine metabolism.

DiGianivittorio P, Hinkel L, Mackinder J, Schutz K, Klein E, Wargo M Microbiology (Reading). 2025; 171(1).

PMID: 39791474 PMC: 11893366. DOI: 10.1099/mic.0.001520.


The genes are important for growth in the presence of sphingosine by promoting sphingosine metabolism.

DiGianivittorio P, Hinkel L, Mackinder J, Schutz K, Klein E, Wargo M bioRxiv. 2024; .

PMID: 39282278 PMC: 11398299. DOI: 10.1101/2024.09.03.611043.

References
1.
Viviani L, Harrison M, Zolin A, Haworth C, Floto R . Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). J Cyst Fibros. 2016; 15(5):619-23. DOI: 10.1016/j.jcf.2016.03.002. View

2.
Elborn J, Blasi F, Burgel P, Peckham D . Role of inhaled antibiotics in the era of highly effective CFTR modulators. Eur Respir Rev. 2023; 32(167). PMC: 9879329. DOI: 10.1183/16000617.0154-2022. View

3.
Umunakwe O, Seegmiller A . Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase. J Lipid Res. 2014; 55(7):1489-97. PMC: 4076094. DOI: 10.1194/jlr.M050369. View

4.
Ernst W, Shome K, Wu C, Gong X, Frizzell R, Aridor M . VAMP-associated Proteins (VAP) as Receptors That Couple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Proteostasis with Lipid Homeostasis. J Biol Chem. 2016; 291(10):5206-20. PMC: 4777854. DOI: 10.1074/jbc.M115.692749. View

5.
Bibel D, Aly R, Shinefield H . Antimicrobial activity of sphingosines. J Invest Dermatol. 1992; 98(3):269-73. DOI: 10.1111/1523-1747.ep12497842. View